ATTENTION NATUS SHAREHOLDERS: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Natus Medical Incorporated; Encourages Investors to Contact the Firm for Additional Infor

SAN DIEGO, April 22, 2016

Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding Natus' business and prospects were false and misleading when made.

The investigation concerns whether Natus disclosed the risk that certain key government supply contracts would, if cancelled, cause a material decline in the Company's revenues and profitability. On April 4, 2016, Natus announced that revenue for the first quarter of 2016 is expected to be approximately $87.5 million versus previous guidance of $91.5 million to $92.5 million. Jim Hawkins, President and CEO, stated, "Pushouts of key orders in both our international and domestic markets led to weaker than expected revenue late in the first quarter". Hawkins further acknowledged, "In addition, we did not have any revenue associated with the Venezuela Ministry of Health contract as we did not receive any prepayments during the quarter".  On this news, shares of Natus fell from a close of $39.64 on April 1, 2016 to close at $31.84 per share the following trading day.

If you are a Natus shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471. If you email, please include your phone number.

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com